Sign inJoin waitlistJoin the waitlist

Ashley Plant-Fox

Associate Professor, Pediatrics · McGaw Medical Center of Northwestern University

Credentials: · · · · · ·

History

McGaw Medical Center of Northwestern University
Present
McGaw Medical Center of Northwestern University
Present

Pediatric Hematology Oncology
Boston Children's Hospital
2013–2016
Pediatrics
University of California-Los Angeles
2010–2013
Stanford University School of Medicine
2006–2010

Research

Ruxolitinib reverses dysregulated T helper cell responses and controls autoimmunity caused by a novel signal transducer and activator of transcription 1 (STAT1) gain-of-function…
Case report · Journal of Allergy and Clinical Immunology · 2017 · 128 citations
Clinical targeted exome-based sequencing in combination with genome-wide copy number profiling: precision medicine analysis of 203 pediatric brain tumors
Neuro-Oncology · 2017 · 70 citations
Autologous tumor lysate-pulsed dendritic cell immunotherapy for pediatric patients with newly diagnosed or recurrent high-grade gliomas
Anticancer Research · 2013 · 67 citations

Anthony Wang
3 papers
Susan Chi
3 papers
Amar Gajjar
2 papers
AF
Andrea Franson
2 papers
AM
Anita Mahajan
2 papers
Bonnie Cole
2 papers
Daniel Bowers
2 papers
Daniel Landi
2 papers
Duncan Stearns
2 papers
GD
Glenn Dranoff
2 papers
GT
Glenn Tisman
2 papers
Jeffrey Helgager
2 papers

Clinical trials

Determine Maximum Tolerated Dose, Safety, and Tolerability of Rhenium (186Re) in Pediatric Recurrent, Refractory or Progressive Ependymoma and High-Grade Glioma
Site PI · Recruiting · Phase 1
Cerenome
2026–2028
PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma
Site PI · Recruiting · Phase 2
Nationwide Children's Hospital
2024–2030
rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG
Site PI · Recruiting · Phase 1
Ann & Robert H Lurie Children's Hospital of Chicago
2022–2027
A Phase 2, Open-Label Study to Evaluate the Safety and Effects of HLX-1502 in Patients With Neurofibromatosis Type 1
Sub-investigator · Recruiting · Phase 2
Healx Limited
2025–2028